Advanced Glycation End Products Evolution after Pancreas-Kidney Transplantation: Plasmatic and Cutaneous Assessments
Table 1
Patients’ demographic and clinical characteristics.
Total group ( = 20)
Before SPKT
Age (years)
36.7 ± 5.4
Female gender
11 (55%)
Time of diabetes (years)
26.0 ± 5.3
Time on dialysis (months)
18 ± 11
HbA1c (%)
8.29 ± 1.61
(HbA1c – mmol/mol)
67.1 ± 17.1
HbA1c ≥9% (≥74.9 mmol/mol)
7 (35%)
Fasting glucose (mg/dL)
304 ± 129
Active smoking (/%)
4 (20%)
Body mass index (BMI) (kg/m2)
22.4 ± 2.6
BMI >25 kg/m2 (/%)
0 (0%)
Hypertension (>130/85 mmHg) (/%)
13 (65%)
After SPKT (12 months)
HbA1c (%)
5.34 ± 0.31
(HbA1c – mmol/mol)
34.9 ± 3.4
HbA1c ≥6% (≥42.1 mmol/mol)
0 (0%)
Fasting glucose (mg/dL)
83 ± 9
e-GFR (mL/min/1.73 m2)
77.5 ± 15.5
Urinary protein excretion (g/24 h)
0.071 ± 0.093
Active smoking (/%)
1 (5%)
BMI (kg/m2)
22.4 ± 2.5
BMI >25 kg/m2 (/%)
2 (10%)
Taking aspirin (/%)
19 (95%)
Hypercholesterolemia (>200 mg/dL) (/%)
1 (5%)
Hypertriglyceridemia (>150 mg/dL) (/%)
2 (10%)
Low HDL-c (/%)
2 (10%)
High LDL-c (/%)
0 (0%)
Taking statins (/%)
1 (5%)
Hypertension (/%)
6 (30%)
Taking ACEI (/%)
3 (15%)
C-reactive protein (CRP) (mg/L)
1.58 ± 1.05
CRP >5 (mg/L)
0 (0%)
e-GFR: estimated glomerular filtration rate (MDRD calculation). Low HDL-cholesterol defined as <40 mg/dL in men and <50 mg/dL in women. ACEI: angiotensin converting enzyme inhibitors.
